Evidence map›Paper›PMID 36322935›Full record

ArticleJournal of medicinal chemistry2022

Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration.

Bin Hu, Kosuke Toda, Xiaoyu Wang, Monika I Antczak, Julianne Smith, Sophie Geboers, Gen Nishikawa, Hongyun Li, Dawn Dawson, Stephen Fink and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Bin HuDepartment of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States.
Kosuke TodaCase Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States.
Xiaoyu WangDepartment of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States.
Monika I AntczakDepartment of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States.
Julianne SmithCase Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States.
Sophie GeboersDepartment of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States.
Gen NishikawaCase Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States.
Hongyun LiCase Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States.
Dawn DawsonCase Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States.
Stephen FinkCase Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States.
Amar B DesaiCase Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States.
Noelle S WilliamsDepartment of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States.
Sanford D MarkowitzCase Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States.
Joseph M ReadyDepartment of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States.ORCID 0000-0003-1305-9581
University Hospitals Cleveland Medical Center · USSouthwestern Medical Center · USUniversity Hospitals of Cleveland · US

Funding

Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and RegenerationRM1GM142002 · NIGMS · UT SOUTHWESTERN MEDICAL CENTER · PI MARKOWITZ, SANFORD D., PIEPER, ANDREW A · 2021 to 2025
$6.9M
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and TreatmentR35CA197442 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI MARKOWITZ, SANFORD D. · 2017 to 2023
$6.6M
Chemical Inhibitors of 15-prostaglandin dehydrogenase Potentiate Hematopoietic Stem Cell TransplantationR01CA216863 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GERSON, STANTON L., MARKOWITZ, SANFORD D. · 2017 to 2019
$1.9M
Novel Molecular Biomarkers and Therapeutics for Colorectal CancerR50CA211119 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI FINK, STEPHEN PAUL · 2018 to 2022
$774k
NCI NIH HHS R01 CA216863NCI NIH HHS R35 CA197442NCI NIH HHS R50 CA211119NIGMS NIH HHS RM1 GM142002
6 · The paper itself

Abstract

15-Prostaglandin dehydrogenase (15-PGDH) regulates the concentration of prostaglandin E2

Indexed as

Hydroxyprostaglandin DehydrogenasesQuinoxalinesAnimalsColitis, UlcerativeDinoprostoneMice15-hydroxyprostaglandin dehydrogenaseDinoprostoneHydroxyprostaglandin DehydrogenasesQuinoxalines

Identifiers

PMID36322935
PMCPMC9885488
OpenAlexW4308058962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.